LinusBio key facts
as of Oct 2026- Developer of a precision exposome medicine platform designed to analyze the molecular impact of environmental exposures on health.
- LinusBio is valued at approximately $171.2M as of Oct 2026 (last reported valuation).
- It has raised $34.6M; the latest was Later Stage VC ($3.0M) in Jun 2025.
- Notable investors include GreatPoint Ventures, Bow Capital, Crom Capital Management, David Bellet Family Office, Divergent Investments — 9 tracked in total.
- Status: Privately Held (backing).
LinusBio's last reported valuation, Jul 2024. Nothing priced has surfaced since.
- ·Watch LinusBio: the Monday email on marks, rounds and moves
LinusBio funding rounds
No funding rounds for LinusBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
LinusBio valuation
LinusBio's last reported valuation was $171 million in Jul 2024. No priced round, secondary trade or fund mark has surfaced since.
LinusBio investors
9 investors are on record for LinusBio, including GreatPoint Ventures, Bow Capital, Crom Capital Management and David Bellet Family Office.
About LinusBio
Developer of a precision exposome medicine platform designed to analyze the molecular impact of environmental exposures on health. The company offers a temporal exposome sequencing technology, enabling healthcare providers to identify novel biomarkers and improve the diagnosis and treatment of complex conditions like CNS and GI disorders.
- Sector
- Healthcare
- HQ
- North Brunswick, NJ, United States
- Founded
- 2020
- Employees
- 39
- Website
- linusbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.